Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
ALS: early-phase trial registry
10 of 20 indexed ALS trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 10 currently recruiting · #848 of 28,707 conditions by registered trial count
ALS: 20 US clinical trials tracked, 10 recruiting.
ALS is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Amylyx Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition als
OPEN 10 | RECR 50% | LATE 0 | EARLY 6 | RANK #848 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
ALS lists 10 open slots (50% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for ALS on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
ALS is recruiting above its size-band peers.
10 of 20 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of ALS trials is spread across many organizations.
Amylyx Pharmaceuticals accounts for 2 of 20 trials (10%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most ALS trials plan to enrol fewer than 100 people.
Median target enrolment is 75 among the 20 trials that report a genuine target (sentinel values excluded). 13 of those (65%) plan for fewer than 100 participants.
-
ALS splits between interventional and observational designs.
11 interventional and 9 observational studies make up this index (55% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
NYSCF Scientific Discovery Biobank
New York Stem Cell Foundation Research Institute
NCT06203106
ALS/MND Natural History Study Data Repository
Massachusetts General Hospital
NCT05966038
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
University of Pennsylvania
NCT06377033
Amyotrophic Lateral Sclerosis (ALS) Families Project
Columbia University
NCT03865420
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
National Institute of Mental Health (NIMH)
NCT04396873
Multicenter ALS Imaging Study
University of Minnesota
NCT06735014
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals
NCT06665165
Combined Respiratory Training in Persons With ALS
Nova Southeastern University
NCT05913882
ECoG BMI for Motor and Speech Control
Karunesh Ganguly
NCT03698149
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01)
Leigh R. Hochberg, MD, PhD.
NCT06511934
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
Mayo Clinic
NCT03268603
Adenosine 2A Receptor Antagonism and AIH in ALS
University of Florida
NCT05377424
Digital Tools for Assessment of Motor Functions and Falls in ALS
Milton S. Hershey Medical Center
NCT05271435
National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank
US Department of Veterans Affairs
NCT00076154
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
Teva Branded Pharmaceutical Products R&D
NCT00696332
Open Label Extension Study of AMX0035 in Patients With ALS
Amylyx Pharmaceuticals
NCT03488524
Feasibility of an Electrical Impedance Tomography Device for Pulmonary Function Testing in ALS Patients
Beth Israel Deaconess Medical Center
NCT05287958
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Duke University
NCT02457715
Deep Phenotyping in Patients With ALS
Barrow Neurological Institute
NCT02819765
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS
Avera McKennan Hospital & University Health Center
NCT03324399
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on ALS records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on ALS trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this ALS page
20 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 ALS trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amylyx Pharmaceuticals sponsors the most ALS trials on record, review their full trial history before evaluating a specific study. See Amylyx Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ALS condition card totals 20 registered trials; most-linked intervention probiotic; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.